Dissecting new mechanisms of lysosome quality control in health and disease
剖析健康和疾病中溶酶体质量控制的新机制
基本信息
- 批准号:10594038
- 负责人:
- 金额:$ 36.2万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2021
- 资助国家:美国
- 起止时间:2021-04-01 至 2026-03-31
- 项目状态:未结题
- 来源:
- 关键词:AccelerationAcuteAffinityAgingArchitectureAutophagocytosisBindingBiochemicalBiochemistryBiogenesisBiological AssayC-terminalC2 DomainCalciumCatabolismCell Membrane PermeabilityCell ProliferationCell membraneCell physiologyCellsCharacteristicsChemicalsCoupledCytoplasmDYSF geneDataDedicationsDefectDegenerative DisorderDependenceDigestionDiseaseDisease ProgressionDissectionEndowmentEnsureFamilyFamily memberFluorescent ProbesGoalsGolgi ApparatusGrowthHealthHomeostasisImpairmentIn VitroLipid BilayersLysosomesMaintenanceMalignant NeoplasmsMalignant neoplasm of pancreasMass Spectrum AnalysisMeasurementMeasuresMechanical StressMediatingMembraneMembrane ProteinsMetabolicMetabolismMitochondriaMorphologyMuscular DystrophiesMutationMyoblastsNormal CellNutrientOrganellesPancreatic Ductal AdenocarcinomaPathogenesisPathway interactionsPhospholipidsPhosphotransferasesProcessPropertyProtein FamilyProteinsProteomicsQuality ControlReactionRecyclingResistanceRoleRouteSignal TransductionSkeletal MuscleStressTestingTransmembrane Domaincell typecomparativecopingdetection of nutrientin vivoinsightlysosome membranemembermetabolomicsmutantnovelpancreatic ductal adenocarcinoma cellpreservationprogramsrepairedresilienceresponsesealtraffickingtranscription factortumor growth
项目摘要
PROJECT SUMMARY
Lysosomes function as critical nodes for macromolecular recycling, metabolic rewiring, and pro-growth
signaling in cells. Accordingly, defects in lysosome function underlie degenerative diseases and aging while
hyperactivation of lysosomes are associated with cancer. Prior studies have shown that highly aggressive
Pancreatic ductal adenocarcinoma (PDA) cells upregulate lysosome biogenesis and activity to facilitate
degradation, clearance and recycling of incoming cargo material delivered by increased rates of autophagy and
macropinocytosis. Whether qualitative differences endow PDA lysosomes with unique structural and functional
properties to cope with a higher demand for substrate clearance remains unknown. To answer this question, we
have conducted the first comparative proteomics analysis of lysosomes isolated from PDA versus normal cells
and have identified members of the Ferlin family of membrane repair factors, Myoferlin and Dysferlin, as
selectively enriched on the membrane of PDA lysosomes. We propose that Ferlin proteins confer
increased protection against lysosomal membrane stress in PDA cells.
Ferlin proteins are normally localized on the plasma membrane of cell types subjected to heightened
mechanical stress, such as skeletal muscle, where they facilitate repair of the lipid bilayer. Accordingly, mutations
in DYSF are associated with two forms of muscular dystrophy whereby impaired membrane resealing
compromises myoblast maturation, fusion and plasma membrane repair. Therefore, we hypothesize that PDA
cells hijack and repurpose Ferlin proteins at the lysosome membrane to protect the integrity of this organelle. In
support of this hypothesis, our preliminary findings show that PDA lysosomes are more resistant to acute
chemically induced membrane permeabilization relative to normal cells. Mechanistically, lysosome localization
of MYOF is necessary and sufficient for maintenance of lysosome quality control and its suppression leads to
profound defects in lysosome morphology, PDA cell proliferation and in vivo tumor growth. The goal of this
study is to investigate how MYOF functions to protect the lysosome membrane in mechanistic detail and to
determine the impact of blocking lysosome quality control on cellular metabolism, pro-growth signaling and
disease progression. In summary, our discovery and proposed studies will be the first to determine a novel
function for Ferlin proteins at the lysosome membrane and provide insight into how enhanced lysosome quality
control regulates cellular homeostasis and disease pathogenesis.
项目摘要
溶酶体充当大分子回收,代谢重新布和促增长的关键节点
细胞中的信号传导。因此,溶酶体功能缺陷是退化性疾病和衰老的基础
溶酶体的过度激活与癌症有关。先前的研究表明,高度侵略性
胰腺导管腺癌(PDA)细胞上调溶酶体生物发生和活性,以促进
自动噬和增加的货物降解,清除和回收货物的降解和回收
大型细胞增多症。定性差异是否具有独特的结构和功能性的PDA溶酶体
应对底物清除需求较高的属性尚不清楚。要回答这个问题,我们
已经对从PDA与正常细胞分离的溶酶体进行了首次比较蛋白质组学分析
并确定了膜维修因素的Ferlin家族成员,Myoferlin和Dysferlin,
有选择地富集PDA溶酶体的膜。我们建议Ferlin蛋白赋予
对PDA细胞中溶酶体膜应激的保护增加。
FERLIN蛋白通常位于受增强的细胞类型的质膜上
机械应力,例如骨骼肌,在那里促进脂质双层的修复。因此,突变
在DYSF中,有两种形式的肌肉营养不良,从而损害膜重新密封
损害肌细胞成熟,融合和质膜修复。因此,我们假设PDA
细胞在溶酶体膜上劫持和重新利用Ferlin蛋白,以保护该细胞器的完整性。在
对这一假设的支持,我们的初步发现表明,PDA溶酶体对急性更具耐药性
化学诱导的膜通透性相对于正常细胞。从机械上讲,溶酶体定位
Myof的含量是必要的,足以维持溶酶体质量控制及其抑制作用导致
溶酶体形态,PDA细胞增殖和体内肿瘤生长的深刻缺陷。目标的目标
研究是为了调查MyOF如何通过机械细节和到保护溶酶体膜的功能
确定阻断溶酶体质量控制对细胞代谢,促增长信号和的影响
疾病进展。总而言之,我们的发现和拟议的研究将是第一个确定新颖的研究
Ferlin蛋白在溶酶体膜上的功能,并洞悉溶酶体质量的增强
控制调节细胞稳态和疾病发病机理。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Rushika Miriam Perera其他文献
Rushika Miriam Perera的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Rushika Miriam Perera', 18)}}的其他基金
Targeting the autophagy-lysosome system to block pancreatic cancer
靶向自噬溶酶体系统来阻止胰腺癌
- 批准号:
10212065 - 财政年份:2021
- 资助金额:
$ 36.2万 - 项目类别:
Targeting the autophagy-lysosome system to block pancreatic cancer
靶向自噬-溶酶体系统来阻止胰腺癌
- 批准号:
10358483 - 财政年份:2021
- 资助金额:
$ 36.2万 - 项目类别:
Targeting the autophagy-lysosome system to block pancreatic cancer
靶向自噬-溶酶体系统来阻止胰腺癌
- 批准号:
10590682 - 财政年份:2021
- 资助金额:
$ 36.2万 - 项目类别:
Dissecting new mechanisms of lysosome quality control in health and disease
剖析健康和疾病中溶酶体质量控制的新机制
- 批准号:
10186267 - 财政年份:2021
- 资助金额:
$ 36.2万 - 项目类别:
Dissecting new mechanisms of lysosome quality control in health and disease
剖析健康和疾病中溶酶体质量控制的新机制
- 批准号:
10370440 - 财政年份:2021
- 资助金额:
$ 36.2万 - 项目类别:
Identifying Molecular Drivers of Cellular Plasticity in Pancreatic Cancer
识别胰腺癌细胞可塑性的分子驱动因素
- 批准号:
10404053 - 财政年份:2020
- 资助金额:
$ 36.2万 - 项目类别:
Identifying Molecular Drivers of Cellular Plasticity in Pancreatic Cancer
识别胰腺癌细胞可塑性的分子驱动因素
- 批准号:
10626914 - 财政年份:2020
- 资助金额:
$ 36.2万 - 项目类别:
Identifying Molecular Drivers of Cellular Plasticity in Pancreatic Cancer
识别胰腺癌细胞可塑性的分子驱动因素
- 批准号:
10252885 - 财政年份:2020
- 资助金额:
$ 36.2万 - 项目类别:
Identifying Molecular Drivers of Cellular Plasticity in Pancreatic Cancer
识别胰腺癌细胞可塑性的分子驱动因素
- 批准号:
9974205 - 财政年份:2020
- 资助金额:
$ 36.2万 - 项目类别:
相似国自然基金
阿魏酸基天然抗氧化抗炎纳米药物用于急性肾损伤诊疗一体化研究
- 批准号:82302281
- 批准年份:2023
- 资助金额:30 万元
- 项目类别:青年科学基金项目
SGO2/MAD2互作调控肝祖细胞的细胞周期再进入影响急性肝衰竭肝再生的机制研究
- 批准号:82300697
- 批准年份:2023
- 资助金额:30 万元
- 项目类别:青年科学基金项目
基于hemin-MOFs的急性心肌梗塞标志物负背景光电化学-比色双模分析
- 批准号:22304039
- 批准年份:2023
- 资助金额:30 万元
- 项目类别:青年科学基金项目
RNA甲基转移酶NSUN2介导SCD1 mRNA m5C修饰调控急性髓系白血病细胞铁死亡的机制研究
- 批准号:82300173
- 批准年份:2023
- 资助金额:30 万元
- 项目类别:青年科学基金项目
基于IRF5/MYD88信号通路调控巨噬细胞M1极化探讨针刀刺营治疗急性扁桃体炎的机制研究
- 批准号:82360957
- 批准年份:2023
- 资助金额:30 万元
- 项目类别:地区科学基金项目
相似海外基金
B Cell Biology in the Context of Infectious Diseases, Autoimmunity and B Cell Cancers
传染病、自身免疫和 B 细胞癌症背景下的 B 细胞生物学
- 批准号:
10683443 - 财政年份:2023
- 资助金额:
$ 36.2万 - 项目类别:
Multidimensional antibody engineering to enhance the potency and breadth of a betacoronavirus medical countermeasure
多维抗体工程可增强β冠状病毒医学对策的效力和广度
- 批准号:
10699866 - 财政年份:2023
- 资助金额:
$ 36.2万 - 项目类别:
Combining immunogenic peptides and Nef blockade to enhance CD8 T-cell-mediated clearance of HIV-infected cells
结合免疫原性肽和 Nef 阻断来增强 CD8 T 细胞介导的 HIV 感染细胞清除
- 批准号:
10685405 - 财政年份:2022
- 资助金额:
$ 36.2万 - 项目类别:
Cocaine self-administration and cholesterol metabolism
可卡因自我给药和胆固醇代谢
- 批准号:
10670400 - 财政年份:2022
- 资助金额:
$ 36.2万 - 项目类别:
Innovative memantine therapy for neuroprotective effects against ischemic stroke and Alzheimer's disease
创新美金刚疗法对缺血性中风和阿尔茨海默病具有神经保护作用
- 批准号:
10480182 - 财政年份:2022
- 资助金额:
$ 36.2万 - 项目类别: